Study details
Enrolling now
The Safety and Efficacy of Roflumilast Foam in HS
Beth Israel Deaconess Medical Center
NCT IDNCT07263230ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
20
Study length
about 2.8 years
Ages
18+
Locations
1 site in MA
About this study
Researchers are testing the safety and effectiveness of a new treatment called roflumilast foam for people with hidradenitis suppurativa (HS). The trial will last 1005 days and involve applying the foam to affected areas. It is investigating whether this treatment can help improve symptoms associated with HS.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Roflumilast 0.3% topical foam
PhasePhase 2
DrugRoflumilast 0.3% topical foam
Routetopical
Primary goalMean Change from Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
DERMATOLOGICALS
Drug routes
topical
Endpoints
Primary: Mean Change from Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16.